Apogee Therapeutics (APGE) CMO sells 5,500 shares, exercises 4,125 options

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Apogee Therapeutics Chief Medical Officer Carl Dambkowski reported a mix of stock sales and option exercises. On May 6, 2026, he completed open-market sales totaling 5,500 shares of common stock at weighted average prices of $84.60 and $83.92 per share under a pre-arranged Rule 10b5-1 trading plan.

He also exercised 4,125 stock options at an exercise price of $22.86 per share, converting options into common stock. A related option grant covers 175,345 shares that vest in forty-eight equal monthly installments through December 18, 2027, conditioned on his continued service.

Insider Trade Summary 10b5-1

Net Seller: 5,500 shares ($462,784)

Net Sell 4 txns

Insider Dambkowski Carl

Role Chief Medical Officer

Sold 5,500 shs ($463K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	4,125	$0.00	--
Exercise	Common Stock	4,125	$22.86	$94K
Sale	Common Stock	3,700	$83.92	$311K
Sale	Common Stock	1,800	$84.60	$152K

Holdings After Transaction: Stock Option (Right to Buy) — 123,040 shares (Direct, null); Common Stock — 212,523 shares (Direct, null)

Footnotes (1)

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.35 to $84.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.44 to $84.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.

Key Figures

Shares sold (first tranche): 1,800 shares at $84.60 Shares sold (second tranche): 3,700 shares at $83.92 Total shares sold: 5,500 shares +4 more

7 metrics

Shares sold (first tranche) 1,800 shares at $84.60 Open-market common stock sale on May 6, 2026

Shares sold (second tranche) 3,700 shares at $83.92 Open-market common stock sale on May 6, 2026

Total shares sold 5,500 shares Net common stock sales per transaction summary

Options exercised 4,125 shares at $22.86 Stock option exercise converting into common stock

Option grant size 175,345 shares Stock Option (Right to Buy) total underlying shares

Vesting schedule 48 equal monthly installments Option vests through December 18, 2027

Trading plan adoption date September 22, 2025 Rule 10b5-1 plan governing May 6, 2026 sales

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), vest in forty-eight equal monthly installments, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported above is a weighted average price. The shares were sold in multiple transactions..."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) ... represents the right to purchase 175,345 shares of the Issuer's common stock"

vest in forty-eight equal monthly installments financial

"which will vest in forty-eight equal monthly installments through December 18, 2027"

derivative exercise/conversion financial

"transaction_action": "derivative exercise/conversion""

Form 4 Insider Transactions: What Each Field Means →

05/08/2026 - 08:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dambkowski Carl

(Last)

(First)

(Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM

MASSACHUSETTS

02453

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/06/2026		M		4,125	A	$22.86	212,523	D
Common Stock	05/06/2026		S⁽¹⁾		3,700	D	$83.92⁽²⁾	208,823	D
Common Stock	05/06/2026		S⁽¹⁾		1,800	D	$84.6⁽³⁾	207,023	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$22.86	05/06/2026		M			4,125	⁽⁴⁾	12/18/2033	Common Stock	4,125	$0.00	123,040	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.35 to $84.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.44 to $84.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

4. This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.

	/s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Apogee Therapeutics (APGE) report for Carl Dambkowski?

Apogee Therapeutics reported that Chief Medical Officer Carl Dambkowski sold 5,500 shares of common stock and exercised 4,125 stock options. These trades occurred on May 6, 2026 and combined open-market sales with a derivative option exercise.

At what prices did the Apogee Therapeutics (APGE) CMO sell shares?

The CMO’s reported sales used weighted average prices of $84.60 and $83.92 per share. Footnotes note these averages reflect multiple trades within ranges from $83.35 to $84.69, and detailed price breakdowns are available on request from the company or SEC staff.

Were Carl Dambkowski’s Apogee Therapeutics (APGE) stock sales pre-planned?

Yes. A footnote states the May 6, 2026 stock sales were executed under a Rule 10b5-1 trading plan adopted on September 22, 2025. Such pre-arranged plans automate trading and reduce the significance of timing decisions for interpreting insider sentiment.

What stock options did the Apogee Therapeutics (APGE) CMO exercise?

He exercised 4,125 stock options described as a “Stock Option (Right to Buy)” with an exercise price of $22.86 per share. This converted derivative rights into common stock, reflecting part of a broader equity compensation package disclosed in the filing.

How large is the Apogee Therapeutics (APGE) option grant tied to these exercises?

A footnote explains the option represents the right to purchase 175,345 shares of Apogee common stock. The award vests in forty-eight equal monthly installments through December 18, 2027, contingent on Carl Dambkowski’s continued service with the company.

What is the net effect of the Apogee Therapeutics (APGE) CMO’s recent trades?

The Form 4 summary shows 5,500 shares sold and 4,125 options exercised, resulting in net share sales. While the insider reduced common stock exposure, he also continued using and holding option-based equity compensation, combining liquidity with ongoing alignment.